Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0OU3Q
|
||||
| Former ID |
DIB005401
|
||||
| Drug Name |
TAK-058
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Phase 1 | [1] | ||
| Target and Pathway | |||||
| Target(s) | 5-Hydroxytryptamine 3 receptor | Target Info | Antagonist | [2], [3] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02389881) Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants. U.S. National Institutes of Health. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040805) | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.